Martin Højgaard

Martin Højgaard is a clinical oncologist working with phase 1 and 2 trials in solid tumors. He is the principal investigator of more than 30 early-stage clinical trials, mainly focusing on synthetic lethality and targeted therapies. Martin Hojgaard chairs the Danish National Molecular Tumor Board, an entity overseeing more than 1000 patients’ comprehensive genomic profiles annually for allocation to clinical trials and targeted therapy recommendations. Martin Højgaard is on the steering committee of the Nordic Molecular Tumor Board, an academic initiative promoting clinical trial access and patient allocation in the Nordic region of Europe, awareness of emerging molecular target calling, case discussions and attracting sponsored clinical trials to the Nordic region. Martin Højgaard is employed at The Phase 1 Unit, Rigshospitalet, Denmark, the largest early phase clinical trials in the Nordic region.

Click here for Martin Højgaards personal LinkedIn profile
Click here for the company LinkedIn profile
Click here for the company website